PATENT CLAIM ANALYSIS

Application Number: 16114791
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "182000"]

Abstract:
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v): and wherein L 1 , L 2 , L 3 , X 1 , X 2 , Y, R Z4 , R Z5 , R Z6 , n, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , R 6a , R 6b , R 7a , R 7b , R 11a , R 11b , R 14 , R 17 , R 19 , R 20 , R 23a , R 23b , and R 24  are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

Claim (Index 4):
The process of  claim 1 , wherein the coupling agent is methyl propiolate.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 96.0
- Lexical Diversity: 2.15789
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15681983', '13636263', '14811559', '15305801', '15660114']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.746831457948295
- 35 USC 102 Novelty (BERT): 0.5278627375379734
- Combined Prediction Score: 0.7249345859072628
- Mean Citation Score: 272.577978
- Max Citation Score: 275.83017
- Similarity Product: 155.09373846014142

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test